Join
Live feed
·
PRReleasevia Quantisnow
Kazia Therapeutics Limited logo

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

ByQuantisnow·Wall Street's wire, on your screen.
KZIA· Kazia Therapeutics Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KZIA (Kazia Therapeutics Limited) and more on Quantisnow.